Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Danial E Baker

Showing results (1-10 of 171) with videos related to

Pageof 18
Sort By:
Hospital Pharmacy|March 30, 2019
OmadacyclineDanial E Baker
Hospital Pharmacy|October 13, 2016
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Reviews in Gastroenterological Disorders|March 19, 2004
Therapeutic equivalence of mesalamine productsDanial E Baker
Reviews in Gastroenterological Disorders|December 8, 2004
Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibodyDanial E Baker
Reviews in Gastroenterological Disorders|September 8, 2006
MMX mesalamineDanial E Baker
Reviews in Gastroenterological Disorders|November 10, 2009
Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunctionDanial E Baker
Hospital Pharmacy|January 15, 2014
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|January 15, 2014
Nonprescription drug safe use regulatory expansionDanial E Baker
Hospital Pharmacy|January 15, 2014
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|June 25, 2014
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Pageof 18

Showing results (1-10 of 171) with videos related to

Sort By:
Pageof 18
Hospital Pharmacy|March 30, 2019
OmadacyclineDanial E Baker
Hospital Pharmacy|October 13, 2016
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Reviews in Gastroenterological Disorders|March 19, 2004
Therapeutic equivalence of mesalamine productsDanial E Baker
Reviews in Gastroenterological Disorders|December 8, 2004
Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibodyDanial E Baker
Reviews in Gastroenterological Disorders|September 8, 2006
MMX mesalamineDanial E Baker
Reviews in Gastroenterological Disorders|November 10, 2009
Methylnaltrexone bromide: new drug for the treatment of opioid-induced bowel dysfunctionDanial E Baker
Hospital Pharmacy|January 15, 2014
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|January 15, 2014
Nonprescription drug safe use regulatory expansionDanial E Baker
Hospital Pharmacy|January 15, 2014
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Hospital Pharmacy|June 25, 2014
Approvals, Submission, and Important Labeling Changes for US Marketed PharmaceuticalsDanial E Baker
Pageof 18